SEC Form 4 · accession 0001232583-17-000005
Evolent Health, Inc. · EVH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steve Wigginton
Officer — CEO, Valence Health
Period of report
May 1, 2017
Accepted (ET)
May 3, 2017 · 5:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001628908
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | May 1, 2017 | M | 6,000 | $3.84 | A | 364,704 | D | |
| Class A Common StockF2 | May 1, 2017 | S | 6,000 | $23.10 | D | 358,704 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Class A Common Stock Option (right to buy)F3 | $3.84 | May 1, 2017 | M | 6,000 | D | — | Apr 1, 2024 | Class A Common Stock | 6,000 | 417,680 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2016.
- F2The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $22.90-$23.35, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The Class A Common Stock Options exercised began vesting at a rate of 25% annually beginning October 1, 2014.